In this episode, Dr Jin-Xiong She, a scientist with more than 400 publications, over 20,000 citations, and more than $100 million in research funding, explains why he left the top tier of academic medicine to pursue something more urgent: finding better ways to detect decline early and protect healthspan before disease takes hold. He shares what nearly 100,000 NAD tests have uncovered and why he believes biomarker baselines could change the way we think about prevention.

https://www.jinfiniti.com/

https://www.youtube.com/@ProfJinShe

In this episode:

00:00 Welcome and Guest Intro

01:47 From Genomics to Longevity

04:18 T1D TEDDY Study Breakthroughs

06:07 Leaving Academia for Impact

07:37 Healthspan Over Lifespan

10:09 TAO Test Act Optimise

13:20 Choosing Actionable Biomarkers

17:02 Why NAD Tops the List

21:45 NAD Decline and Key Drivers

25:21 Raising NAD Lifestyle vs Supplements

27:51 Athletes' Inflammation and Low NAD

31:54 Optimal NAD Range and Niacin Risks

37:28 SubQ Injections vs Oral NMN Data

41:42 Dosing and Cutting Useless Supplements

43:52 Access Economics and Policy Ideas

46:50 Industry Adoption and Big Names

47:59 Supplement Market Problems

50:17 Rapid Fire and Closing Takeaways

52:04 Final Summary and Goodbye